Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 8CNS 8NET 3

Conditions

Neuroendocrine Tumors 9Pheochromocytoma 3Paraganglioma 3Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 33-Iodobenzylguanidine 3Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Biopsy 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Paraganglioma × 3-Iodobenzylguanidine × NET × Clear all
NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡